Suppr超能文献

经皮孤立肝脏化学灌注诱导晚期肝细胞癌长期缓解

Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion.

作者信息

Ku Y, Iwasaki T, Fukumoto T, Tominaga M, Muramatsu S, Kusunoki N, Sugimoto T, Suzuki Y, Kuroda Y, Saitoh Y, Sako M, Matsumoto S, Hirota S, Obara H

机构信息

Department of Surgery I, Kobe University School of Medicine, Japan.

出版信息

Ann Surg. 1998 Apr;227(4):519-26. doi: 10.1097/00000658-199804000-00012.

Abstract

OBJECTIVE

The aim of this study was to report the long-term results of percutaneous isolated liver chemoperfusion with hepatic venous isolation and charcoal hemoperfusion (HVI-CHP) in patients with multiple advanced hepatocellular carcinoma (HCC).

SUMMARY BACKGROUND DATA

The results of conventional chemotherapy including regional and systemic chemotherapy in patients with HCC remain dismal, and long-term survivors after treatment are rare among patients with multiple advanced HCC. In an effort to improve this situation, we previously developed a novel system of percutaneous isolated liver chemoperfusion with HVI-CHP.

METHODS

Doxorubicin (60 to 150 mg/m2) was administered via the hepatic artery, under conditions of extracorporeal drug elimination by HVI-CHP in 28 consecutive patients with advanced HCC (39 total treatments). Hepatic venous isolation and charcoal hemoperfusion was accomplished mainly by the single catheter technique using a newly developed 4-lumen-balloon catheter, which was used to isolate and capture total hepatic venous outflow and, at the same time, to direct the filtered blood to the right atrium.

RESULTS

Complete remission was achieved in five patients, of which four received repeated treatments (two or three times). Although 1 of 5 patients with complete remission died of pulmonary metastases at 8 months, the other 4 remain healthy and free of disease at 20, 24, 27, and 42 months after the first treatment. Partial responses were observed in 12 patients. Duration of response in responders (complete and partial) with repeated treatments was significantly longer than that with a single treatment (p = 0.01). The overall survival rate by the Kaplan-Meier method was 39.7% at 5 years. The treatments were well-tolerated, and the primary side effects were mild to moderate chemical hepatitis and reversible myelosuppression.

CONCLUSIONS

The results suggest that percutaneous isolated liver chemoperfusion with HVI-CHP is an effective palliative treatment in the majority of patients and yields long-term complete remission in some patients with multiple advanced HCC.

摘要

目的

本研究旨在报告经皮孤立肝化学灌注联合肝静脉隔离及活性炭血液灌注(HVI-CHP)治疗多发性晚期肝细胞癌(HCC)患者的长期结果。

总结背景数据

包括区域化疗和全身化疗在内的传统化疗在HCC患者中的结果仍然不佳,在多发性晚期HCC患者中,治疗后长期存活者很少。为了改善这种情况,我们先前开发了一种新型的经皮孤立肝化学灌注联合HVI-CHP系统。

方法

在28例连续的晚期HCC患者(共39次治疗)中,通过HVI-CHP进行体外药物清除的条件下,经肝动脉给予阿霉素(60至150mg/m²)。肝静脉隔离及活性炭血液灌注主要通过使用新开发的四腔球囊导管的单导管技术完成,该导管用于隔离和捕获全部肝静脉流出物,同时将过滤后的血液导向右心房。

结果

5例患者实现完全缓解,其中4例接受了重复治疗(2次或3次)。虽然5例完全缓解患者中有1例在8个月时死于肺转移,但其他4例在首次治疗后20、24、27和42个月时仍健康且无疾病。12例患者观察到部分缓解。重复治疗的缓解者(完全缓解和部分缓解)的缓解持续时间明显长于单次治疗者(p = 0.01)。采用Kaplan-Meier法计算的5年总生存率为39.7%。治疗耐受性良好,主要副作用为轻度至中度化学性肝炎和可逆性骨髓抑制。

结论

结果表明,经皮孤立肝化学灌注联合HVI-CHP对大多数患者是一种有效的姑息治疗方法,并且在一些多发性晚期HCC患者中可产生长期完全缓解。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验